Scientists have for the first time looked deep into the protein structure that may determine our vision - and discovered that ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South ...

A new research perspective was published in , Volume 16, on April 4, 2025, titled "GSK3β activation is a key driver of ...

That is below the 30% rate reported at an interim stage of the study at the International Liver Congress earlier this year, but still sufficient for GSK to take the drug forward into a phase 3 ...

GlaxoSmithKline has agreed a $3.3 billion takeover of US biotech Affinivax ... years has been dominated by Pfizer's Prevnar franchise. GSK said it is paying $2.1 billion upfront for Cambridge ...

Despite competitive pressures and external risks, Unilever's robust presence in emerging markets and strategic focus on top ...

British drugs firm GSK has been accused of burying a report said to prove a link between its medication Zantac and cancer, a new lawsuit has claimed. A pension fund has filed a class action ...

New research reveals that the immune checkpoint molecule Tim-3 plays a critical role in how microglia, the brain’s immune cells, respond to Alzheimer’s disease.